Home | My Profile | Contact Us
Research Trends Products  |   order gateway  |   author gateway  |   editor gateway  
Register | Forgot Password

Author Resources
 Author Gateway
 Article submission guidelines

Editor Resources
 Editor/Referee Gateway

 Regional Subscription Agents/Distributors
Current Topics in Pharmacology   Volumes    Volume 21 
A new structured helical DPT-peptide containing a short canine adenovirus E4orf4 PP2A1-binding sequence inhibits the PI3k survival pathway in human radio-resistant U87G glioblastoma cells
J. H. Colle, A. Garcia
Pages: 49 - 54
Number of pages: 6
Current Topics in Pharmacology
Volume 21 

Copyright © 2017 Research Trends. All rights reserved

Radio-resistance of glioblastoma cells is a major challenge for developing an efficient therapy. Previous studies have established that constitutive activity of the PI3K-Akt pathway and radio-induction of cellular senescence are involved in radio-resistance of U87G cells. Herein, using a rational molecular design, we identified a new potential anti-tumor DPT-peptide, named DPT-E4orf423-38, that combines the HIV-1 Tat shuttle plus the canine adenoviral type 2 E4orf423-38 PP2A1-binding sequence. This new chimeric sequence is a helical peptide that inhibits the survival of U87G cell line. In addition we found that DPT-E4orf423-38 inhibited Akt-phosphorylation (ser473), and decreased the growth of highly radio-resistant U87G cells. Finally DPT-E4orf423-38 also decreased the growth of X-irradiated (2Gy) U87G senescent cells. Together our results suggest that DPT-E4orf423-38 alone or combined with irradiation might be clinically evaluated as a potential therapeutic molecule against PI3K-dependent and human radio-resistant and radio-senescent glioblastomas.
View Full Article  


Buy this article
Buy this volume
Subscribe to this title
Shopping Cart

Quick Links
Search Products
Browse in Alphabetical Order : Journals
Browse by Subject Classification : Journals

Ordering Information Ordering Information
Downloadable forms Downloadable Forms